#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Cancer survivors are increasingly using cannabis to manage treatment-related symptoms, yet clinicians often lack knowledge about its safety and efficacy in this population, creating a communication gap that may compromise symptom management and treatment adherence. Understanding these divergent perspectives is essential for clinicians to provide evidence-based counseling about cannabis use, drug interactions with cancer medications, and realistic expectations about symptom relief. Bridging this provider-patient divide could improve shared decision-making and help oncology teams better support survivors’ quality of life during and after cancer treatment.
A cross-sectional study examining attitudes toward medical cannabis among cancer survivors and their healthcare providers revealed a significant disconnect in perspectives on its therapeutic value and safety profile. While cancer survivors reported substantial interest in cannabis for symptom management of pain, nausea, and anxiety, oncologists and other providers expressed greater hesitancy, citing insufficient clinical evidence and concerns about drug interactions with cancer treatments. This gap between patient preferences and provider comfort levels may create barriers to open discussion about cannabis use and limit patients’ access to information about potential benefits and risks. The findings highlight an important gap in provider education regarding cannabinoid pharmacology and the emerging evidence base for cannabis in supportive cancer care. Clinicians managing cancer patients should proactively discuss cannabis use, familiarize themselves with current evidence on cannabinoid efficacy and safety, and recognize that patient interest in these therapies is likely to increase. To bridge this divide, oncologists and primary care providers should develop competency in cannabis counseling to help cancer survivors make informed decisions about symptom management options.
“This observational study highlights a real disconnect between what patients report experiencing and what many providers feel confident recommending, which tells us we need better training and more rigorous clinical data rather than assuming either group has it entirely right. The anecdotal benefits cancer patients describe deserve serious attention, but we’re still working with limited high-quality evidence in this population, so the most honest conversation with patients involves acknowledging both what seems to help them and what we still don’t know about long-term effects and optimal dosing.”
💊 While cancer survivors increasingly report using cannabis to manage treatment-related symptoms like pain, nausea, and anxiety, the gap between patient enthusiasm and provider skepticism highlighted in this research warrants careful consideration in clinical conversations. Providers may hesitate due to limited high-quality evidence specific to cancer populations, drug interaction concerns with oncology regimens, and variable legal and regulatory frameworks that complicate counseling. However, dismissing patients’ lived experiences risks damaging therapeutic relationships and may drive undisclosed use that prevents proper monitoring for adverse effects or interactions. The discordance also reflects legitimate knowledge gaps: robust clinical trials examining cannabis efficacy and safety in cancer survivors remain scarce, and cannabinoid pharmacokinetics can be unpredictable across individuals and products. Oncology providers should acknowledge this uncertainty directly with patients, explore their specific symptom management goals, document any cannabis use in the medical record, and consider evidence-based alternatives or complementary approaches
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
